CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients
- 5 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (6), 879-886
- https://doi.org/10.1007/s00228-020-03076-8
Abstract
Purpose Genetic polymorphisms have been associated with variation in the metabolism of tacrolimus (TAC) in kidney transplant patients. This study is aimed at assessing the impact of allelic variants of CYP3A5 and PPARA genes on the pharmacokinetics (PK) of TAC in Brazilian kidney transplant recipients in the first-year post-transplant. Methods A total of 127 patients were included for genetic evaluation. Genomic DNA was isolated from peripheral blood and real-time PCR was used to analyze the main polymorphisms described for the genes CYP3A5 (rs776746; C > G) and PPARA (rs4823613; A > G and rs4253728; G > A). Results CYP3A5 expressors showed a lower Co/dose ratio than non-expressors, with the median values of this parameter PPARA variant homozygotes had a lower Co/D ratio than wild allele carriers in the 12-month post-transplant period, with a median value of 0.65 ng/mL/mg. In the CYP3A5 expressers, the presence of the variant homozygous genotype PPARA was associated with a lower value of Co/D compared with the other genotypic groups at month 12. Conclusion In the population under study, polymorphisms on CYP3A5 and PPARA were identified as determining and independent factors associated with the reduction of Co/D of TAC. Thus, the genotyping of these genetic variants may be a useful tool for the individualized prescription of TAC in kidney transplant patients.Keywords
Funding Information
- Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão
This publication has 40 references indexed in Scilit:
- Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant PatientsTherapeutic Drug Monitoring, 2014
- A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant RecipientsClinical Chemistry, 2011
- Suppression of NF-κB by Cyclosporin A and Tacrolimus (FK506) via Induction of the C/EBP Family: Implication for Unfolded Protein ResponseThe Journal of Immunology, 2009
- CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental StudyAmerican Journal of Transplantation, 2006
- Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipientsPharmacogenetics and Genomics, 2006
- EFFECT OFCYP3A5POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRODrug Metabolism and Disposition, 2006
- Immunosuppressive Drugs for Kidney TransplantationThe New England Journal of Medicine, 2004
- Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2Transplantation, 2003
- Early versus late acute rejection episodes in renal transplantationTransplantation, 2003
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996The New England Journal of Medicine, 2000